| Long Term Follow-up Assessment of a Phase I Trial of Angiogenic Gene Therapy Using Direct Intramyocardial Administration of an Adenovirus Vector Expressing the VEGF121 cDNA for the Treatment of Diffuse Coronary Artery Disease. | |
| | |
MedLine Citation:
|
PMID: 23137122 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Aims: Based on studies in experimental animals demonstrating that AdVEGF121, an E1-E3- serotype 5 adenovirus coding for the 121 isoform of vascular endothelial growth factor (VEGF), could mediate the generation of new blood vessels and reverse coronary ischemia, a clinical study of direct myocardial administration of AdVEGF121 was initiated in patients with late stage, diffuse coronary artery disease. This study provides long term (median 11.8 yr) follow-up on these patients. Results: From 1997 to 1999, AdVEGF121 was administered by direct myocardial injection to an area of reversible ischemia in 31 patients with severe coronary disease; either as an adjunct to conventional coronary artery bypass grafting (Group A) or as minimally invasive sole (MIS) therapy using a mini-thoracotomy (Group B). There was no control group; the study participants served as the controls. The 5 and 10 year survival was 10/15 (67%) and 6/15 (40%) for the Group A patients, and 11/16 (69%) and 5/16 (31%) for Group B sole therapy patients, respectively. In comparison, maximal medical therapy in comparable groups in the literature have 3 to 5 yr survival rate of 52 to 59%. For the survivors, the angina score for Group A was 3.4 ± 0.5 at time 0 and 1.9 ± 1.0 at last follow-up, and for Group B it was 3.4 ± 0.6 and 2.0 ± 1.1, respectively. The incidences of malignancy and retinopathy were no greater than that expected for the age-matched general population. Conclusions: Adenovirus-mediated VEGF direct myocardial administration to patients with severe coronary artery disease is safe, and future larger trials are warranted to assess efficacy. |
| | |
Authors:
|
Eileen Finnin; Michael Halbreiner; Odelya Pagovich; Matthew Fakhoury; Todd Ronsengart; Muath Bishawi; Charleen Hollmann; Ronald Crystal |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-11-8 |
Journal Detail:
|
Title: Human gene therapy Volume: - ISSN: 1557-7422 ISO Abbreviation: Hum. Gene Ther. Publication Date: 2012 Nov |
Date Detail:
|
Created Date: 2012-11-9 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9008950 Medline TA: Hum Gene Ther Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Stony Brook, United States; geneticmedicine8@med.cornell.edu. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The use of contact lenses during water-polo play: A 20-year study of Japanese college players.
Next Document: New Antifeedant C(20) Terpenoids from Leucosceptrum canum.